Trial Profile
Prospective, Randomized, Crossover Trial Comparing Recombinant Von Willebrand Factor (rVWF) vs. Tranexamic Acid (TA) to Minimize Menorrhagia in Women With Von Willebrand Disease: The VWD Minimize Study
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 14 Feb 2024
Price :
$35
*
At a glance
- Drugs Von Willebrand factor (Primary) ; Tranexamic acid
- Indications Von Willebrand disease
- Focus Therapeutic Use
- Acronyms VWDMin
- 07 Feb 2024 Status changed from active, no longer recruiting to discontinued early due to slow recruitment..
- 02 Jun 2023 Planned End Date changed from 31 May 2023 to 31 Dec 2024.
- 02 Jun 2023 Planned primary completion date changed from 31 Dec 2022 to 21 Mar 2024.